Structured evidence table for Bovine Colostrum Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Bovine Colostrum Gut Health Randomized Trial | The review was conducted in accordance with PRISMA guidelines, and study quality was assessed using Cochrane risk-of-bias tools. | 1 | Goluch Z (2026) | The Effects of Colostrum Bovinum Supplementation on Human Body Fat Content and/or Blood Lipid Profile: A Systematic Review of Clinical Trials. |
| Bovine Colostrum Gut Health Randomized Trial | One study in older adults reported that COL supplementation at 60 g/day for 8 weeks significantly reduced body fat percentage by 0.4% ( p p < 0.05). | 1 | Goluch Z (2026) | The Effects of Colostrum Bovinum Supplementation on Human Body Fat Content and/or Blood Lipid Profile: A Systematic Review of Clinical Trials. |
| Bovine Colostrum Gut Health Randomized Trial | In individuals with type 2 diabetes, COL supplementation at 10 g/day for 4 weeks significantly reduced total cholesterol (TC) and triglyceride levels in both men and women, by 8.27% vs. | 1 | Goluch Z (2026) | The Effects of Colostrum Bovinum Supplementation on Human Body Fat Content and/or Blood Lipid Profile: A Systematic Review of Clinical Trials. |
| Bovine Colostrum Gut Health Randomized Trial | Bovine colostrum (COL) is widely used in dietary supplements, and previous studies have suggested its potential benefits for immune function, selected clinical conditions, wound healing, and athletic performance. | 1 | Goluch Z (2026) | The Effects of Colostrum Bovinum Supplementation on Human Body Fat Content and/or Blood Lipid Profile: A Systematic Review of Clinical Trials. |
| Bovine Colostrum Gut Health Randomized Trial | Moreover, children with CD frequently exhibit a reduction in the gut microbiome bacteria (Bacteroidetes and Firmicutes), which may associated with the disruption of the epithelial intestinal barrier [,]. | 1 | Marind Ervine Chastine (2026) | Gut Health Responses to Nutritional Interventions in Paediatric Crohn’s Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review |
| Bovine Colostrum Gut Health Randomized Trial | 8 8 9 10 11 Some pharmacological strategies have been proposed to improve intestinal barrier function in celiac disease; however, the evidence regarding IBD remains limited []. | 1 | Marind Ervine Chastine (2026) | Gut Health Responses to Nutritional Interventions in Paediatric Crohn’s Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review |
| Bovine Colostrum Gut Health Randomized Trial | However, the extent to which diet-induced alterations in the gut environment contribute to a tight mucosal barrier or further conversely influence the risk of disease relapse remains unknown. | 1 | Marind Ervine Chastine (2026) | Gut Health Responses to Nutritional Interventions in Paediatric Crohn’s Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review |
| Bovine Colostrum Gut Health Randomized Trial | 1 2 3 3 Crohn’s disease (CD) is a type of inflammatory bowel disease (IBD) that infiltrates all layers of the intestinal wall []. | 1 | Marind Ervine Chastine (2026) | Gut Health Responses to Nutritional Interventions in Paediatric Crohn’s Disease, Including the Potential Outcomes of Mucosal Barrier Preservation: A Systematic Review |
Source documents